Genotype and phenotype in plasma cells

Background

Treatment of AL amyloidosis is chemotherapy targeting abnormal bone marrow plasma cells. The characteristics of these cells determines the treatment outcomes. This study seeks to characterise in detail the abnormal plasma cells by flow cytometry, DNA analysis and exome sequencing.

What the trial involves for patients

All patients with AL amyloidosis need a bone marrow test as a part of the diagnostic work up for amyloidosis and for response assessment at the end of treatment. This study seeks an additional bone marrow sample as well as the usual diagnostic sample.

Who can take part in the trial?

Patients with systemic AL amyloidosis may participate in this trial, starting either at the time of diagnosis or after completion of treatment.

Outcomes

It is hoped that the detailed analysis of genetic and other characteristics of abnormal plasma cells in patients with AL amyloidosis will improve understanding of development of disease and response to treatment.

Timing

This study is ongoing at the NAC.